<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38509699</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>A phase 3 randomized, open-label study evaluating the immunogenicity and safety of concomitant and staggered administration of a live, pentavalent rotavirus vaccine and an inactivated poliomyelitis vaccine in healthy infants in China.</ArticleTitle><Pagination><StartPage>2324538</StartPage><MedlinePgn>2324538</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2324538</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2024.2324538</ELocationID><Abstract><AbstractText>This open-label, randomized, phase 3 study in China (V260-074; NCT04481191) evaluated the immunogenicity and safety of concomitant and staggered administration of three doses of an oral, live, pentavalent rotavirus vaccine (RV5) and three doses of an intramuscular, inactivated poliomyelitis vaccine (IPV) in 400 healthy infants. The primary objective was the non-inferiority of neutralizing antibody (nAb) responses in the concomitant- versus the staggered-use groups. Antibody responses were measured at baseline and 1-month post-dose 3 (PD3). Parents/legal guardians recorded adverse events for 30 or 15 d after study vaccinations in the concomitant-use or staggered-use groups, respectively. At PD3, &gt;98% of participants seroconverted to all three poliovirus types, and the primary objective was met as lower bounds of the two-sided 95% CI for between-group difference in nAb seroconversion percentages ranged from - 4.3% to - 1.6%, for all poliovirus types, <i>p</i> &lt; .001. At PD3, geometric mean titers (GMTs) of nAb responses to poliovirus types 1, 2, and 3 in the concomitant-use group and the staggered-use group were comparable; 100% of participants had nAb titers ≥1:8 and ≥1:64 for all poliovirus types. Anti-rotavirus serotype-specific IgA GMTs and participants with ≥3-fold rise in postvaccination titers from baseline were comparable between groups. Administration of RV5 and IPV was well tolerated with comparable safety profiles in both groups. The immunogenicity of IPV in the concomitant-use group was non-inferior to the staggered-use group and RV5 was immunogenic in both groups. No safety concerns were identified. These data support the concomitant use of RV5 and IPV in healthy Chinese infants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shaomin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biological Products Surveillance and Evaluation, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ying</LastName><ForeName>Zhifang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Respiratory Virus Vaccine, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Biological Products Surveillance and Evaluation, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yebin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Vaccine Clinical Research Office, Yangchun Center for Disease Control and Prevention, Yangchun, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Meilian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Vaccine Clinical Research Office, Yangchun Center for Disease Control and Prevention, Yangchun, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Zhuhang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Biological Products Surveillance and Evaluation, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ou</LastName><ForeName>Zhiqiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Biological Products Surveillance and Evaluation, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Yuyi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Biological Products Surveillance and Evaluation, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hepatitis Virus and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Guixiu</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical Research, MSD Research and Development (China) Co. Ltd., Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Weiwei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Biostatistics and Research Decision Sciences, MSD Research and Development (China) Co. Ltd., Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Biostatistics and Research Decision Sciences, MSD Research and Development (China) Co. Ltd., Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shou</LastName><ForeName>Qiong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Biostatistics and Research Decision Sciences, MSD Research and Development (China) Co. Ltd., Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Minghuan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Research, MSD Research and Development (China) Co. Ltd., Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Xueyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Clinical Research, MSD Research and Development (China) Co. Ltd., Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tu</LastName><ForeName>Yingmei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Infectious Diseases/Vaccines Clinical Research, Merck &amp; Co. Inc., Rahway, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stek</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infectious Diseases/Vaccines Clinical Research, Merck &amp; Co. Inc., Rahway, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartzel</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biostatistics and Research Decision Sciences, Merck &amp; Co. Inc., Rahway, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Changgui</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Control of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jikai</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Directors Office, Guangdong Provincial Institute of Biological Products and Materia Medica, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022243">Rotavirus Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022243" MajorTopicYN="Y">Rotavirus Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Poliomyelitis</Keyword><Keyword MajorTopicYN="N">concomitant</Keyword><Keyword MajorTopicYN="N">gastroenteritis</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">inactivated polio vaccine</Keyword><Keyword MajorTopicYN="N">pentavalent rotavirus vaccine</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList><CoiStatement>Zhifang Ying, Yan Liu, Yong Zhang, and Changgui Li are all current employees of the National Institutes for Food and Drug Control (NIFDC), which is responsible for the immunogenicity sample testing. Guixiu Liu, Weiwei Zhao, Rong Fu, Qiong Shou, Minghuan Zheng, and Xueyan Liao are current or former employees of MSD Research and Development (China) Co., Ltd., Beijing, China, a subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA and may own stock and/or options in Merck &amp; Co., Inc., Rahway, NJ, USA. Yingmei Tu, Jon Stek, and Jonathan Hartzel are current or former employees of Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA and may own stock and/or options in Merck &amp; Co., Inc., Rahway, NJ, USA. Shaomin Chen, Yuan Li, Yebin Yu, Meilian Huang, Zhuhang Huang, Zhiqiang Ou, Yuyi Liao, and Jikai Zhang have no conflicts to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>21</Day><Hour>2</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38509699</ArticleId><ArticleId IdType="pmc">PMC10962606</ArticleId><ArticleId IdType="doi">10.1080/21645515.2024.2324538</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization . Rotavirus. [accessed 2023 Sep
19]. https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccines-quality/rotavirus.</Citation></Reference><Reference><Citation>Troeger C, Khalil IA, Rao PC, Cao S, Blacker BF, Ahmed T, Armah G, Bines JE, Brewer TG, Colombara DV, et al. Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years. JAMA Pediatr. 2018;172:958–10. doi:10.1001/jamapediatrics.2018.1960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2018.1960</ArticleId><ArticleId IdType="pmc">PMC6233802</ArticleId><ArticleId IdType="pubmed">30105384</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Duan Z, Payne DC, Yen C, Pan X, Chang Z, Liu N, Ye J, Ren X, Tate JE, et al. Rotavirus-specific and overall diarrhea mortality in Chinese children younger than 5 years: 2003 to 2012. Pediatr Infect Dis J. 2015;34:e233–7. doi:10.1097/INF.0000000000000799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000000799</ArticleId><ArticleId IdType="pmc">PMC4618544</ArticleId><ArticleId IdType="pubmed">26083587</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Yen C, Yin ZD, Li YX, Liu N, Liu YM, Wang HQ, Cui FQ, Gregory CJ, Tate TE, et al. The public health burden of rotavirus disease in children younger than five years and considerations for rotavirus vaccine introduction in China. Pediatr Infect Dis J. 2016;35:392–8. doi:10.1097/INF.0000000000001327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000001327</ArticleId><ArticleId IdType="pmc">PMC6502223</ArticleId><ArticleId IdType="pubmed">27626917</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Rotavirus vaccines: WHO position paper – July 2021. Wkly Epidemiol Rec. 96(28):301. [accessed 2023 Sep
19]. https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/position-papers/rotavirus.</Citation></Reference><Reference><Citation>Fu C, Tate JE, Jiang B.. Effectiveness of Lanzhou lamb rotavirus vaccine against hospitalized gastroenteritis: further analysis and update. Hum Vaccin. 2010;6:953. doi:10.4161/hv.6.11.12847.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.6.11.12847</ArticleId><ArticleId IdType="pubmed">20980802</ArticleId></ArticleIdList></Reference><Reference><Citation>National Medical Products Administration . List of approved domestic vaccine products in China. Rotavirus (Live) Vaccine, Oral. [accessed 2023 Sep
19]. https://www.nmpa.gov.cn/datasearch/en/search-info-en.html?nmpa=aWQ95Zu96I2v5YeG5a2XUzIwMDEwMDAyJml0ZW1JZD0yYzliYTM4MTc5ZDA4ZjRmMDE3OWQxM2NhNGY0MDA0ZQ==.</Citation></Reference><Reference><Citation>RotaTeq . Local product circular. Shanghai: MSD China; 2018.  [accessed 2024 Mar 4]. https://www.msdchina.com.cn/wp-content/uploads/2023/09/%E4%B9%90%E5%84%BF%E5%BE%B7-%E8%AF%B4%E6%98%8E%E4%B9%A6-%E8%BF%9B%E5%8F%A3semi-%E7%AE%80%E7%89%88%EF%BC%88%E6%96%B9%E6%AD%A3%E9%BB%91%EF%BC%89-23.7.26-%E6%9B%B2%E7%BA%BF.pdf.</Citation></Reference><Reference><Citation>National Medical Products Administration . List of approved domestic vaccine products in China. Reassortant Rotavirus Vaccine, Live, Oral, Trivalent (Vero Cell). [accessed 2023 Sep
19]. https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9YjFjOWVlMTQyOGJhMzkyZTFmMTdiN2ZkYjk0M2M1ZjQmaXRlbUlkPWZmODA4MDgxODNjYWQ3NTAwMTg0MDg4MWY4NDgxNzlm.</Citation></Reference><Reference><Citation>RotaTeq [prescribing information]. Rahway (NJ): Merck Sharp &amp; Dohme LLC; 2023. 
Apr. [accessed 2024 Mar 7]. https://www.fda.gov/media/75718/download.</Citation></Reference><Reference><Citation>Mo Z, Mo Y, Li M, Tao J, Yang X, Kong J, Wei D, Fu B, Liao X, Chu J, et al. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial. Vaccine. 2017;35:5897–904. doi:10.1016/j.vaccine.2017.08.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.08.081</ArticleId><ArticleId IdType="pubmed">28935470</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez ZM, Goveia MG, Stek JE, Dallas MJ, Boslego JW, DiNubile MJ, Heaton PM. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatr Infect Dis J. 2007;26:221–7. doi:10.1097/01.inf.0000254391.71103.e8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.inf.0000254391.71103.e8</ArticleId><ArticleId IdType="pubmed">17484218</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciarlet M, Sani-Grosso R, Yuan G, Liu GF, Heaton PM, Gottesdiener KM, Arredondo JL, Schödel F. Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine. Pediatr Infect Dis J. 2008;27:874–80. doi:10.1097/INF.0b013e3181782780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0b013e3181782780</ArticleId><ArticleId IdType="pubmed">18756184</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciarlet M, He S, Lai S, Petrecz M, Yuan G, Liu GF, Mikviman E, Heaton M, Panzer F, Rose T, et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatr Infect Dis J. 2009;28:177–81. doi:10.1097/INF.0b013e31818c0161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0b013e31818c0161</ArticleId><ArticleId IdType="pubmed">19209092</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo Z, Ma X, Luo P, Mo Y, Kaplan SS, Shou Q, Zheng M, Hille DA, Arnold BA; V260-024 Study Group, et al. Immunogenicity of pentavalent rotavirus vaccine in Chinese infants. Vaccine. 2019;37:1836–43. doi:10.1016/j.vaccine.2019.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.02.018</ArticleId><ArticleId IdType="pubmed">30808567</ArticleId></ArticleIdList></Reference><Reference><Citation>Vesikari T, Karvonen A, Borrow R, Kitchin N, Baudin M, Thomas S, Figuet A. Results from a randomized clinical trial of coadministration of RotaTeq, a pentavalent rotavirus vaccine, and NeisVac-C, a meningococcal serogroup C conjugate vaccine. Clin Vaccine Immunol. 2011;18:878–84. doi:10.1128/CVI.00437-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00437-10</ArticleId><ArticleId IdType="pmc">PMC3122533</ArticleId><ArticleId IdType="pubmed">21389149</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Position statement safety and pre-qualification of oral polio vaccine (OPV); 2006. 
May. [accessed 2023 Sep
19]. https://polioeradication.org/wp-content/uploads/2016/09/Position-statement_OPVsafety.pdf.</Citation></Reference><Reference><Citation>World Health Organization . Polio vaccines: WHO position paper – March 2016. Wkly Epidemiol Rec. 2016;91(12):145. [accessed 2023 Sep
19]. https://www.who.int/publications/i/item/WHO-WER9112.
</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Polio eradication and endgame strategic plan 2013–2018. Geneva (Switzerland): World Health Organization; 2013. Polio Global Eradication Initiative. [accessed 2023 Sep
19]. https://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_A4.pdf.</Citation></Reference><Reference><Citation>World Health Organization . Meeting of the strategic advisory group of experts on immunization, November 2012 - conclusions and recommendations. Wkly Epidemiol Rec. 2013;88:1. [accessed 2023 Sep
19]. https://apps.who.int/iris/bitstream/handle/10665/242011/WER8801_1-16.PDF?sequence=1&amp;isAllowed=y.
</Citation><ArticleIdList><ArticleId IdType="pubmed">23311010</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Polio eradication strategy 2022–2026: delivering on a promise. Geneva (Switzerland): World Health Organization; 2021. Polio Global Eradication Initiative. [accessed 2023 Sep
19]. https://apps.who.int/iris/bitstream/handle/10665/345967/9789240031937-eng.pdf.</Citation></Reference><Reference><Citation>World Health Organization . Poliomyelitis (polio) in China. [accessed 2023 Sep
19]. https://www.who.int/china/health-topics/poliomyelitis-(polio).</Citation></Reference><Reference><Citation>National Health Commission of the People’s Republic of China . Childhood immunization schedule for national immunization program vaccines - China (version 2021). China CDC Wkly. 2021;3:1101–8. doi:10.46234/ccdcw2021.270.</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2021.270</ArticleId><ArticleId IdType="pmc">PMC8855077</ArticleId><ArticleId IdType="pubmed">35186365</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Recommendations to assure the quality, safety and efficacy of poliomyelitis vaccines (inactivated), Annex 3, TRS No 1024. Amendment to Annex 3 of the WHO Technical Report Series, No. 993; 2020. 
Nov
6. [accessed 2023 Sep
19]. https://www.who.int/publications/m/item/poliomyelitis-vaccines-annex-3-trs-no-1024.</Citation></Reference><Reference><Citation>Nathanson N. David Bodian’s contribution to the development of poliovirus vaccine. Am J Epidemiol. 2005;161:207–212. doi:10.1093/aje/kwi033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwi033</ArticleId><ArticleId IdType="pubmed">15671252</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin S, Anh DD, Zaman K, Yunus M, Mai le TP, Thiem VD, Azim T, Victor VC, Dallas MJ, Steele AD, et al. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam. Vaccine. 2012;30(suppl 1):106–13. doi:10.1016/j.vaccine.2011.11.091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.11.091</ArticleId><ArticleId IdType="pubmed">22520119</ArticleId></ArticleIdList></Reference><Reference><Citation>Armah GE, Breiman RF, Tapia MD, Dallas MJ, Neuzil KM, Binka FN, Sow SO, Ojwando J, Ciarlet M, Steele AD. Immunogenicity of the pentavalent rotavirus vaccine in African infants. Vaccine. 2012;30(suppl 1):A86–A93. doi:10.1016/j.vaccine.2011.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.10.006</ArticleId><ArticleId IdType="pubmed">22520142</ArticleId></ArticleIdList></Reference><Reference><Citation>Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–26. doi:10.1002/sim.4780040211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.4780040211</ArticleId><ArticleId IdType="pubmed">4023479</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>